Optimized antibodies that target CD19

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9803020
SERIAL NO

13959587

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcgγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
XENCOR INC465 NORTH HALSTEAD STREET SUITE 200 PASADENA CA 91107

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bernett, Matthew J Monrovia, US 82 1810
Chu, Seung Yup Cypress, US 31 615
Desjarlais, John R Pasadena, US 195 6468
Karki, Sher Bahadur Pomona, US 139 6592
Lazar, Gregory Alan Arcadia, US 159 7599
Pong, Erik WeiKing Temple City, US 11 238
Richards, John O Duane, US 16 428
Zhukovsky, Eugene Alexander West Hollywood, US 14 211

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Apr 30, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00